Motilal Oswal reiterates buy on Laurus Labs with INR1,980 target
AI مارکیٹ کا خلاصہ
Laurus Labs reported a strong 1QFY27 earnings beat, with revenue, EBITDA, and net profit exceeding expectations on CDMO and formulations strength. Commercial and late-stage clinical supplies, plus a customer's global regulatory approval, improve order visibility and support continued manufacturing investment. The news is equity-specific and signals improving operating leverage and demand durability, but has limited broader cross-asset market impact.
اثر کی سطح
● لو
متاثرہ اثاثے
NCCOGOLD2USD/USDT+0.84%
AI تجزیاتی سمجھ · NCCOGOLD2USD/USDTAI تجزیاتی سمجھ
▲ Bullish
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
Laurus Labs reported 1QFY27 results, with revenue, EBITDA and net profit beating market expectations by 14%, 31% and 53%, respectively, marking a record quarter. The growth was led by its CDMO and formulations (FDF) businesses, supported by commercial supplies and deliveries for late-stage clinical projects. It also cited improved order visibility after a customer received global regulatory approval for a product, according to Motilal Oswal. Based on this, the brokerage set a target price of INR1,980, valuing the stock at 65x forward earnings.
